trial · primary record
selexipag (Uptravi)
Pulmonary Arterial Hypertension
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 63 |
| Primary completion | 2026-12-31 |
| Primary endpoint | Area Under the Plasma Concentration-time Curve Over a Dose Interval at Steady State of Selexipag and Its Metabolite ACT-333679 Combined (AUCτ, ss, Combined) |
| Registry ID | NCT03492177 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:13.011Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03492177
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.